Document is current
Any future updates will be listed below
-
Authors
Zhang, Zhen https://orcid.org/0000-0001-9074-2689
Baxter, Amy E. https://orcid.org/0000-0002-1555-0713
Ren, Diqiu
Qin, Kunhua https://orcid.org/0000-0002-1388-2888
Chen, Zeyu
Collins, Sierra M.
Huang, Hua
Komar, Chad A.
Bailer, Peter F. https://orcid.org/0000-0002-3865-6932
Parker, Jared B. https://orcid.org/0000-0002-3405-1581
Blobel, Gerd A.
Kohli, Rahul M. https://orcid.org/0000-0002-7689-5678
Wherry, E. John https://orcid.org/0000-0003-0477-1956
Berger, Shelley L.
Shi, Junwei https://orcid.org/0000-0002-8427-6316
- License Information
-
More Information
Article History
Received: 3 August 2022
Accepted: 22 March 2023
First Online: 24 April 2023
Competing interests
: Z.Z., A.E.B., Z.C., J.B.P., R.M.K., E.J.W., S.L.B. and J.S. through the University of Pennsylvania have filed a patent application on aspects of this work. E.J.W. is a member of the Parker Institute for Cancer Immunotherapy which supported this study. E.J.W. is an advisor for Danger Bio, Janssen, New Limit, Marengo, Pluto Immunotherapeutics Related Sciences, Santa Ana Bio, Synthekine and Surface Oncology. E.J.W. is a founder of and holds stock in Surface Oncology, Danger Bio and Arsenal Biosciences. R.M.K. is on the Scientific Advisory Board for Life Edit, Inc.
